Maynard Um
-
-
-
-
-
-
-
Pasithea Therapeutics (KTTA) Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004
-
-
-
-
-
-
-
Pasithea Therapeutics (KTTA) Reports Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from Phase 1 Trial of PAS-004
-
419,966 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

